New hope for kids with rare eye tumors: drug combo shows promise
NCT ID NCT07378657
First seen Feb 01, 2026 · Last updated Jun 12, 2026 · Updated 13 times
Summary
This study tests a systematic approach to treat orbital lymphatic malformation in children and teens. Participants receive either injection sclerotherapy, the drug sirolimus, or both, depending on their condition. The goal is to see if sirolimus is safe and effective at shrinking the malformation and easing symptoms. About 30 people aged 1-18 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORBITAL LYMPHATIC MALFORMATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ain Shams University
RECRUITINGCairo, Cairo Governorate, 11321, Egypt
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.